Advanced searches left 3/3

Primary Myelofibrosis - Europe PMC

Summarized by Plex Scholar
Last Updated: 22 July 2022

* If you want to update the article please login/register

Triple-Negative Primary Myelofibrosis: a Bone Marrow Pathology Group (BMPG) study

In more than 80% of the cases, primary myelofibrosis is a clonal myeloproliferative neoplasm fueled by canonical gene mutations in JAK2, CALR, or MPL. The morphologic and genetic variations of TN-PMF relative to canonical driver mutations have not been well investigated, especially in comparison to conventional PMF. TN-PMF patients were more likely to have thrombocytopenia and less likely to have organomegaly relative to the control group and less likely to have organomegaly. With TN-PMF, the bone marrow revealed fewer granulocytic elements and increased frequent dyserythropoiesis. Targeted NGS revealed a lower incidence of ASXL1 mutations but an enrichment of ASXL1/SRSF2 co-mutations.

Source link: https://europepmc.org/article/PPR/PPR508727


Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.

According to the WHO 2016 guidelines in China, 56 ET patients, 19 pre-PMF patients, and 43 overt PMF patients were retrospectively reviewed the clinical parameters, haematologic evidence, and genetic abnormalities of patients with myeloproliferative neoplasms. Pre-PMF patients had higher leukocyte counts [14. 2 u/L vs. 9 0 yrs. P 0. 003], evidence of splenomegaly and hypertension [14. 1 u00d7 10 9 /L, P = 0. 001], respectively versus ET patients compared to ET patients [67 years vs. P 0. 006], as well as higher leukocyte counts [14. 2 u00d7 10 9 vs [6 vs [1 vs [1 vs [1 vs [1 vs [1 vs [1] [3 vs [1 vs [1] [3 vs [1 vs [1 vs [1] vs [6 vs [1 vs [1] vs [1] vs [1]. In patients with overt PMF patients with overt PMF and overt PMF patients, the frequency of EP300 mutations was significantly higher in pre-PMF patients compared to ET and overt PMF patients, and WT1 was more commonly overexpressed in patients with overt PMF than in those with ET or pre-PMF.

Source link: https://europepmc.org/article/MED/35731275

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions